Balicatib巴利卡替,354813-19-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Balicatib

CAS No. : 354813-19-7

MCE 国际站：Balicatib

产品活性：Balicatib (AAE581) 是一种有效的、具有口服活性和选择性的 组织蛋白酶K cathepsin K 抑制剂，对组织蛋白酶 K、组织蛋白酶 B、组织蛋白酶 L、组织蛋白酶 S 的IC₅₀ 值分别为 22、61、48、2900 nM。Balicatib 抑制骨转换，降低骨形成率。Balicatib 具有研究骨质疏松症的潜力。

研究领域：Metabolic Enzyme/Protease

作用靶点：Cathepsin

In Vitro: Balicatib (0-10 µM) shows less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 µM in human dermal fibroblasts.

In Vivo: Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  Angiogenesis-Related Compound Library  |  Targeted Diversity Library  |  Membrane Protein-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Leupeptin hemisulfate  |  N-Ethylmaleimide  |  Aloxistatin  |  PMSF  |  E-64  |  CA-074 methyl ester  |  Papain  |  Calpeptin  |  CA-074  |  p-Aminophenylmercuric acetate  |  Z-FY-CHO  |  LY 3000328  |  Odanacatib  |  SID 26681509  |  Z-FA-FMK  |  K777  |  Cathepsin inhibitor 1  |  L-006235  |  Petesicatib  |  Z-LVG-CHN2  |  GSK-2793660  |  LHVS  |  Chymostatin  |  Z-WEHD-FMK  |  Cathepsin X-IN-1  |  S130  |  3-Epiursolic Acid  |  KGP94  |  VBY-825  |  Cathepsin C-IN-5

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds